FDA Nod For Roche’s Columvi Brings Third Anti-CD20 Bispecific To Market
The company is touting the drug’s fixed-duration treatment as an advantage for patients, while the new drug class has ignited discussion around their use in the community oncology setting.
You may also be interested in...
Highlights of recent submissions for approval from the Pink Sheet’s US FDA Performance Tracker
The companies unveiled results showing a high overall response rate from the anti-CD20xCD3 bispecific as competition heats up between various players in the space.
The Danish group, along with partner AbbVie, is all set for a commercial battle with Roche as Epkinly hits the US market for refractory diffuse large B-cell lymphoma a few weeks ahead of expected approval for the Swiss major’s same-in-class rival glofitamab.